Rapid Dose Therapeutics Inc. has entered into a strategic partnership with Aphria Inc. (NYSE:APHA). The two have agreed to build upon their previous agreement. The expansion of the agreement will boost the introduction of RDT’s QuickStrip delivery technology into the German cannabis market. Aphria will have exclusive global rights to produce, distribute and sell QuickStrip products.

The amendment of the agreement is timely given the rapid growth of the cannabis industry. It is an additional advantage in accelerating the adoption of RDT’s QuickStrip into key European cannabis markets.

In the recent past, the leading global cannabis company has been seeking ways to integrate cannabis into people’s lives. It is worth noting that from Germany’s population of 82 million people, 30,000 are cannabis consumers. On the other hand, the annual legal consumption stands at 7,200 kilograms, which means a majority cannot access it.

The company’s approach aims at ensuring the availability of cannabis to those who need it.  The technology is not only precise but it is also an oral fast-dissolving drug delivery system. It offers a unique, smoke-free nutraceutical product.  In addition, it is easy to use and very discreet.

Speaking about the company’s intention to revolutionize the way consumers’ access cannabis, Aphria’s Chief Commercial Officer, Jakob Ripshtein affirmed, “Aphria is committed to bringing breakthrough innovations to the global cannabis market, which is why we are excited to introduce RDT as a strategic innovation partner.”

The development of healthcare manufacturing industry

The Canadian med-tech company, RDT, is one of the many companies focused on improving the healthcare manufacturing industry. Its primary target is clinical research and product development and a further keenness on nutraceutical, pharmaceutical and cannabis industries.

The company’s CEO Mark Upsdell says that they will continue to build strategic global partnerships, which will be of service to the global market.